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Abstract
The inherent immunomodulatory capacity of mesenchymal stem/progenitor cells (MSPCs) encouraged initiation of
multiple clinical trials. Release criteria for therapeutic MSPCs cover identity, purity and safety but appropriate
potency assessment is often missing. Reports on functional heterogeneity of MSPCs created additional uncertainty
regarding donor and organ/source selection. We established a robust immunomodulation potency assay
based on pooling responder leukocytes to minimize individual immune response variability. Comparing
various MSPCs revealed significant potency inconsistency and generally diminished allo-immunosuppression
compared to dose-dependent inhibition of mitogenesis. Gamma-irradiation to block unintended MSPC
proliferation did not prohibit chondrogenesis and osteogenesis in vivo, indicating the need for alternative
safety strategies.
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Introduction
High expectations in the therapeutic potential of mesen-
chymal stem/progenitor cells (MSPCs) led to the initiation
of >500 clinical trials mainly testing the major histocom-
patibility (MHC) antigen-independent immunomodula-
tory and trophic capacity of autologous and allogeneic
MSPCs propagated from various organs (558 studies reg-
istered by 4 November 2015; www.clinicaltrials.gov search
term =mesenchymal stem cell) [1, 2]. The general concept
of regenerative stem cell therapy is based on evidence that
stem/progenitor cells can contribute to the regeneration
of damaged organs, improve their function or even cure
diseases [3, 4]. Therapeutic application of culture-
expanded MSPCs was initiated >20 years ago to support
hematopoietic stem cell engraftment [5]. Repair of large
bone defects by bone marrow (BM)-MSPCs [6] and
immune suppressive therapy for steroid-refractory
graft-versus-host disease [7, 8] encouraged an extended
spectrum of regenerative and immunomodulatory ap-
plications. Measurable effects despite lack of sustained en-
graftment of transplanted MSPCs led to the current view
favoring trophic and immunomodulatory MSPC functions
to be decisive for therapeutic effects [1, 2, 5].
However, still incomplete mechanistic insight and ab-
sence of predictive biomarkers or potency assays con-
strain projectable clinical applicability of advanced
MSPC therapies [9]. Selection of suitable MSPC donors,
organ sources, propagation procedures, and cell doses,
as well as mode and timing of application is complicated
by functional MSPC heterogeneity within a given tissue
and also between different organs [10, 11]. Contradictory
data demonstrating superiority of certain MSPCs and
impaired efficiency of freshly thawed compared to
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culture-derived cells may at least in part depend on
variable readout assay formats [12–16]. This added a
level of uncertainty to the ongoing clinical trials that
frequently employ off-the-shelf MSPCs which are
thawed upon application without appropriate potency in-
formation at the bedside. Robust ‘potency assays as com-
panion to trials’ are thus urgently needed [9]. Inspired by
previous attempts of pooling therapeutic MSPCs [17], the
pooling of cord blood leukocytes for transplantation [18]
and our longstanding experience with pooled human
platelet lysate (pHPL) as prevailing animal serum replace-
ment for efficient cell propagation [19–22], we hypothe-
sized that pooling both responder T cells as well as
inhibitory MSPCs may help to overcome the variability of
individual donor-derived cells in a potency assay.
Here we introduce a robust potency assay using inhib-
ition of pooled polyclonal T-lymphocyte proliferation (i)
after mitogen or antibody stimulation as well as (ii) due
to allo-antigen-driven mixed leukocyte reaction (MLR).
Pooled organ-specific reference MSPCs were used as a
nominator to qualify individual donor MSPC potency
for inhibiting mitogen-induced as well as MLR-driven
T-cell proliferation in parallel for direct comparison.
Leukocytes from ten donors were pooled to counter-
balance individual immune response variability. Cells
were pre-labeled with carboxyfluorescein and cryopre-
served in aliquots for instant and reproducible off-the-shelf
use. Based on clinical practice, MSPCs were tested immedi-
ately after thawing (off-the-shelf) or after an approximate
72-hour ‘rescue culture’ for their potency to inhibit both
polyclonal and allogeneic T-cell proliferation. MSPCs from
five random human BM, white adipose tissue (WAT) and
umbilical cord (UC) donors were analyzed individually or
as a pool. A supplementary safety measure was intended by
testing 30 Gy irradiation of the MSPCs to minimize the risk
of continued proliferation after application.
Here we show that all MSPCs displayed significant
dose-dependent suppression of T-cell mitogenesis.
Despite significant individual variation we observed
comparable overall suppression of mitogen-induced
T-cell proliferation by the different organ-derived MSPCs.
The inhibition of a multidirectional allo-response within
the pool of ten peripheral blood mononuclear cell
(PBMC) preparations was less efficient by many, but
not all, of the MSPCs, presumably indicating a par-
ticular level of potency variability. Pooling multiple
donor-derived MSPCs compensated inter-individual
variation and allowed us to compare individual donor
MSPC immunosuppression potency with their organo-
typic reference MSPC pool. Irradiation did not signifi-
cantly hamper MSPC functionality, but a note of
caution has to be drawn due to the maintained chon-
drogenic and osteogenic differentiation of 30 Gy irra-
diated BM-MSPCs in vivo.
Methods
Cell isolation, culture, and immunophenotyping
Approval was obtained for human cell and tissue sample
collection from the Institutional Review Board (protocols
19–252, 18–243, 21–060, 19–284 and 415-E/1776/4-
2014, Ethics Committee of the province of Salzburg).
Adult samples were collected in accordance with the
Declaration of Helsinki after written informed consent
from healthy volunteers. Donor age is documented in
Additional file 1 (Table S1). UC samples were collected
after written informed consent by the mother-to-be
obtained prior to delivery of full-term pregnancies.
MSPCs from BM and UC were isolated and expanded
under animal serum-free conditions using pHPL to re-
place fetal bovine serum and their purity, identity and
viability was characterized by flow cytometry as previ-
ously described [21, 23, 24]. WAT-MSPCs were obtained
from stromal vascular fractions of WAT and character-
ized as published [25]. MSPCs were tested either directly
after thawing and 2 × washing (off-the-shelf ) or after an
approximate 72-hour rescue culture to revert a putative
freeze/thaw-induced functional damage [14]. PBMCs
were isolated by density centrifugation from random
donor buffy coats as described [20].
T-cell proliferation assay
Immunomodulatory potency of MSPCs was determined
as described [20] with modifications as follows. PBMCs
from ten random donors (i.e., 1 × 1010 PBMCs derived
from ten buffy coats) were pooled in 500 mL pre-warmed
phosphate-buffered saline (37 °C; Sigma) for staining with
carboxyfluorescein succinimidyl ester (CFSE, 2 μM,
15 minutes, 37 °C; Sigma) in the dark at a cell dens-
ity of 2 × 107 PBMCs/mL. The reaction was stopped
by adding an equal amount of RPMI-1640 medium
(Sigma) supplemented with 10 % human blood group
AB serum. After washing twice in RPMI/10 % AB
serum, 200 aliquots of 5 × 107 CFSE-labeled PBMCs
could be cryopreserved in liquid nitrogen as described
[26] for off-the-shelf use as reference responders in
multiple subsequent experiments. Based on prelimin-
ary titration experiments comparing various PBMC
and MSPC numbers in different cell culture plate for-
mats, 3 × 105 CFSE pre-labeled PBMCs resuspended
in RPMI-1640 supplemented with 10 % pHPL, 2 IU/mL
preservative-free heparin (Biochrom), 2 mM L-glutamine,
10 mM HEPES (Gibco), 100 IU/mL penicillin and
100 μg/mL streptomycin (Sigma) were plated per well
in triplicate in 96-well flat-bottomed plates (Corning).
T-cell proliferation was determined in the absence or
presence of 5 μg/ml phytohemagglutinin (PHA; Sigma) or
CD3/CD28 beads (1:1 ratio; Invitrogen) following manu-
facturer’s instructions with or without graded numbers of
MSPCs (250 μL total volume per well) in limited threefold
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dilution as indicated in the results section. MSPCs were
irradiated (30 Gy; Cs-139 Source, Blobeam 2000 Gamma
irradiator, GSM) as indicated in the results section. Corre-
sponding paired MSPC samples were mock-irradiated
(i.e., were transported together with the irradiated cells
but left standing outside the irradiation device at room
temperature).
For transwell experiments, randomly selected samples
from one of each BM-, WAT- and UC-MSPC donors
were seeded in 24-well plates (Corning) in RPMI-1640
assay medium at different ratios as indicated in the re-
sults section (3 × 105, 1 × 105, 3 × 104, 1 × 104 cells per
well, total volume 500 μl, to reach a MSPC:PBMC ratio
of 1:1, 1:3, 1:10 and 1:30, respectively) at 37 °C. RPMI
assay medium (100 μL) either with PHA (final concen-
tration 5 μg/ml for day 4 mitogenesis measurements) or
without additional stimulus (for untreated samples and
day 7 MLR measurements) was added per 24-well to get
a total volume of 600 μl after 24 hours. Transwell poly-
ester membrane cell culture inserts (0.4 μm pore size,
0.33 cm2 matching the growth area of a 96-well plate
well; Corning) were transferred to all 24-wells before
adding 100 μl CFSE-labeled pooled PBMCs (3 × 105
cells/transwell insert) either with or without PHA stimu-
lus (final concentration 5 μg/ml). In parallel, the stand-
ard immune modulation assay allowing cell–cell contact
as described above was performed with aliquots of the
same cell populations in flat-bottomed 96-well plates.
Both assay formats were cultured for 4 and 7 days before
the proliferation of viable CD3+ cells was analyzed via
flow cytometry. All cultures were performed in humidi-
fied ambient air incubators (Binder CB210) at 37 °C and
5 % CO2.
T-cell proliferation was determined using a Gallios
10-color flow cytometer and the Kaluza G1.0 software
(both Coulter). Viable 7-aminoactinomycin-D-excluding
(7-AAD−; BD Pharmingen) CD3-APC+ (eBioscience) T
cells were analyzed after 4 to 7 days. Proliferation kinetics
and population distribution were analyzed using Modfit
4.1 software (Verity). A MLR is known to occur as a
consequence of pooling multiple individual donor-
derived PBMC preparations. Taking advantage of this
phenomenon, allogeneic MLR-driven polyclonal T-cell
proliferation was determined in addition in the ab-
sence or presence of serially threefold diluted num-
bers of MSPCs.
Bone formation in vivo
All mouse experiments were approved by the Institutional
Animal Care and Use Committee (Stanford Administra-
tive Panel on Laboratory Animal Care no. 22264) and in
adherence to the US National Institutes of Health’s Guide
for the Care and Use of Laboratory Animals. Previous re-
sults demonstrated that BM-MSPCs can form a human
bone and hematopoietic marrow niche via a vascularized
cartilage intermediate when injected subcutaneously into
immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice (6–18 weeks old; Jackson Laboratory) [27]. Using
this model, we tested whether 30 Gy irradiated BM-
MSPCs can differentiate (as can native non-irradiated
BM-MSPCs) in vivo essentially as described [27]. Prior to
application, BM-MSPCs were either irradiated (30 Gy,
Caesium-137 irradiator) or left non-irradiated. Cells were
resuspended in matrigel-equivalent matrix (Millipore)
and injected subcutaneously (four injections per ani-
mal, 2 × 106 cells per injection, two injections with ir-
radiated and non-irradiated cells in the left and right
flank of each animal, respectively). Differentiation of
cells within the plugs was analyzed after 6, 9 and
12 weeks as described [27].
Statistical analysis
Values are presented as mean ± standard deviation (SD).
Prism version 6.00 for Windows (GraphPad Software)
was used for one-way analysis of variance statistical ana-
lysis. p values < 0.05 were considered significant.
Results and discussion
In an initial series of experiments we confirmed that
individual buffy coat-derived PBMCs displayed a signifi-
cant variability of T-cell proliferation in response to
polyclonal PHA stimulation (Fig. 1 and Additional file 2:
Figure S1A). This is also in accordance with recently
published data showing >50 % variation of individual
donor T-cell proliferation after polyclonal stimulation
[28]. This confirmed that individual responder cells do
not allow for reproducible monitoring of MSPC immuno-
suppression potency. Pooling ten random donor-derived
PBMCs resulted in a significant time-dependent MLR
beyond day 4 and increasing until day 7 due to cross-
stimulation of the mixed PBMCs in the absence of
additional external stimuli. Mitogen (PHA) or CD3/CD28
crosslinking-driven polyclonal responses at day 4 were
still significantly higher than the MLR (Additional file 2:
Figure S1B). We selected PHA-driven polyclonal mitogen-
esis at day 4 as well as allogeneic MLR-based polyclonal
T-cell proliferation at day 7 as a dual strategy to test the
potential of different MSPCs for inhibition of T-cell prolif-
eration. Validating this assay format we proved that UC-
MSPCs from a randomly selected donor could sufficiently
inhibit both the mitogenesis and the allogeneic MLR of
pooled PBMCs in a time course testing 4 to 7 days of
assay duration (Additional file 2: Figure 1B and S1C). The
gating strategy based on these experiments is shown in
Additional file 3 (Figure S2). A schematic illustrated sum-
mary of the robust dual potency assay format is shown in
Fig. 2. Using this assay format the PHA-driven prolif-
eration may well be replaced by using other stimuli
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of B cells and natural killer cell proliferation com-
bined with addition of CD19 and CD56 antibodies.
MSPCs from various tissues can display substantial
differences in their capacity to inhibit immune responses
despite common immunophenotype and tri-lineage
differentiation capacity [13, 29]. MSPCs used in this
study were previously isolated from BM, WAT and UC
and did not reveal significant phenotypic differences as
published [27]. Their tri-lineage osteo-, chondro- and
adipogenic differentiation was also confirmed previously
indicating quantitative differences resulting from an
organ-specific epigenomic signature [27]. When testing
fifteen individual BM-, WAT-, and UC-MSPC donors
(five donors per source) we observed a significant inhib-
ition of pooled polyclonal T-cell mitogenesis by MSPCs
from all three sources at 1:3 and 1:10 ratio. At a 1:30
ratio all MSPCs except cultured BM-MSPCs signifi-
cantly inhibited T-cell mitogenesis (Additional file 4:
Figure S3A–C). These data confirmed previously
reported evidence for inferior immunosuppressive
potency of BM-MSPCs [12, 13]. Whether this lack of
immunosuppression of the BM-MSPCs tested in dif-
ferent centers may also translate to reduced efficiency of
BM-MSPCs compared to MSPCs from other sources in
vivo will be indicated soon as a result of several ongoing
clinical trials.
Comparing the individual MSPC preparations which
were all propagated under identical conditions in alpha-
MEM/10 % pHPL and cryopreserved at early passage for
subsequent use, a profound variation in their potency to
inhibit T-cell proliferation became obvious. It may be
hypothesized that for selected donors a freeze/thaw-re-
lated damage resulted in a profound loss of potency
(Fig. 3). We speculate that, in addition to the obvious
donor variation, differences during cell processing and
in the freezing/thawing protocols may contribute to this
phenomenon [13–16]. This may also result from hetero-
geneity of MSPCs derived from the same organ-of-origin
of different donors in different laboratories [16]. In any
case the established variability of different MSPC prepa-
rations is emphasizing the need for a robust potency
assay.
Next we aimed to determine whether freshly thawed
compared to cultured individual donor-derived MSPC
inhibitory effectiveness can be qualified relative to a pool
of reference cells. Therefore, we tested their potency to
inhibit polyclonal T-cell proliferation either individually
or combined as organotypic reference pools. Results
revealed significant differences between individual donors
compared to their organotypic reference (Fig. 3a, b). Par-
ticular MSPCs from BM (donor one, D1) and WAT
(donor eight, D8) displayed higher inhibitory potential
when tested immediately after thawing (off-the-shelf)
compared to corresponding cells tested after a rescue cul-
ture period. MSPCs from other donors showed impaired
inhibitory potency thus reproducing published results
[14]. Most but not all aliquots of the same MSPCs also
significantly inhibited allogeneic MLR-induced prolifera-
tion of the same PBMC pool until day 7 in the absence of
mitogen. Numerous MSPCs were less efficient in inhibit-
ing the MLR than the PHA-driven mitogenesis. Some
(WAT donors six and nine and UC donor 12; D6, D9 and
Fig. 1 Individual or pooled donor polyclonal T-cell proliferation. a
Mean ± SD proliferation of five random single donor buffy coat-derived
CFSE-labeled peripheral blood mononuclear cells (PBMCs) in the
absence (grey bars) or presence of phytohemagglutinin (+PHA,
green bars) after 4 or 7 days indicating significant donor variation.
b Simultaneous inhibition of mitogenic and alloimmunogenic T-cell
proliferation by umbilical cord (UC)-derived MSPCs was tested. CFSE
pre-labeled cryopreserved pooled PBMCs (pPBMCs) were seeded in the
absence of MSPCs without (grey bars) or with PHA (green bars) or in
the presence of UC-MSPC without (light red bars; inhibition of
allo-MLR) or with PHA (red bars; inhibition of additional mitogenesis) at
an MSPC:PBMC ratio of 1:3. The time course of proliferation between
days 4 to 7 is shown in Additional file 2 (Figure S1C). Mean ± SD results
from representative experiments (n = 5 in a and b). Significant
differences are indicated (*p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001)
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D12, respectively) showed at least comparable inhibitory
potency. Although significant individual variability was
observed, both conditions indicated superiority of UC-
and WAT-MSPCs over BM-MSPCs (Fig. 3c, d). Such data
may be interpreted in favor of including potency assays in
the release criteria of advanced cell therapy medicinal
products to better select MSPC donors (in the case of
third party or allogeneic MSPC products) and processing
Fig. 2 Illustrated potency assay strategy. Ten randomly obtained buffy coats from healthy donors can be processed in parallel to isolate
approximately 1 × 109 peripheral blood mononuclear cells (PBMCs) per donor, pooled, labeled with carboxyfluorescein (CFSE) and cryopreserved
in appropriate aliquots (e.g., 200 aliquots of 1 × 107 pre-labeled pooled PBMCs (pPBMC)) for subsequent off-the-shelf use as responder cells in the
potency assay. Individual mesenchymal stem/progenitor cells (MSPC) from donor or organ origin of choice (e.g., bone marrow (BM), white adipose
tissue (WAT), umbilical cord (UC); color code corresponding to Fig. 1) can be tested off-the-shelf or after rescue culture (with or without gamma
irradiation (±Rx)) to test their potency to inhibit mitogen (e.g., PHA)-driven pPBMC proliferation until day 4 (d4), or to inhibit the allogeneic mixed
lymphocyte reaction (MLR) of the same pPBMC batch until day 7 (d7). Representative CD3+ T-cell proliferation kinetics (Modfit analysis) in the
absence (top histograms), or presence of regulatory MSPCs (bottom histograms) indicating maximum number of proliferated populations
(top histograms) and the effect of MSPC-mediated inhibition of T-cell proliferation (bottom histograms) are shown
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Fig. 3 (See legend on next page.)
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methodology (i.e., off-the-shelf use versus rescue culture
of cryopreserved MSPCs).
To address the question whether the T-cell inhibitory
function of MSPCs in this assay format is cell contact-
dependent we performed additional experiments directly
comparing randomly selected MSPCs from BM, WAT
and UC in parallel either in direct cell–cell contact with
the pooled PBMCs or in transwell cultures separating
MSPCs (in the lower compartment) from PBMCs (in the
transwell insert). Results revealed significant inhibition
of PHA-induced T-cell mitogenesis independent of cell–
cell contact. Inhibition of T-cell mitogenesis was signifi-
cantly more efficient at PBMC:MSPC ratios of 1:1 and
1:10 at direct cell–cell contact. The allogeneic MLR
resulting from cross-stimulation of the pooled PBMCs
in the same assay format at day 7 was more significantly
inhibited by UC-MSPCs at most PBMC:MSPC ratios. In-
hibition of the MLR by BM- and UC-MSPCs was less ef-
ficient thus in part resembling data in Fig. 3 and
published results. Also in the allogeneic MLR situation,
depending on the PBMC:MSPC ratio, a cell–cell
contact-independent inhibition of T-cell proliferation
was observed (Additional file 5: Figure S4). Whether the
simple standard assay testing MSPCs in direct contact
with PBMCs, rather than the more complex transwell
assay, might be able to predict the therapeutic MSPC
potency in vivo needs to be determined in prospective
clinical trials. Furthermore, we evaluated if 30 Gy
gamma-irradiation of freshly thawed or cultured BM-
MSPCs can be introduced as a putative safety measure
before cells will be applied in vivo. Our results showed
that irradiation did not influence their immunosuppres-
sive potency (Fig. 4a). Interestingly, 30 Gy irradiation did
not affect the differentiation potential of BM-MSPCs.
We analyzed cartilage and bone formation of irradiated
and non-irradiated BM-MSPCs in NSG mice and found
that despite irradiation human Vimentin+ BM-MSPCs
survived for up to 12 weeks in the immunocompromized
animals and maintained their potential to form bone via a
vascularized cartilage intermediate as recently described
[27]. Hematoxylin and eosin as well as Movat’s penta-
chrome staining clearly demonstrated hypertrophic cartil-
age, osteoid and mineralized bone formation accompanied
by immigration of murine marrow (Fig. 4b). This outcome
extends a recent observation by Bianco and coworkers
[30] showing that cartilage constructs generated from hu-
man BM-MSPCs ex vivo maintain their bone formation
potential even when irradiated before transplantation into
immunodeficient mice. These authors elegantly demon-
strated that cartilage differentiation of BM-MSPCs in vitro
is reversible and can be reverted, despite irradiation, in
vivo, resulting in the generation of stromal hematopoietic
niche-forming cells [30]. The goal of our experiments, in
this study, was to determine whether BM-MSPCs are still
capable of initiating patent chondrogenesis and subsequent
osteogenesis after irradiation in advance of differentiation.
Our observation that 30 Gy irradiation of human
BM-MSPCs ex vivo did not impair cartilage and bone
formation in vivo does not exclude the possibility that
Vimentin+ stromal niche elements observed particu-
larly in areas of hematopoiesis immigration could be
derived from intermediate chondrocytes. A note of
caution thus needs to be drawn regarding applicability
of irradiated BM-MSPCs which might maintain their
differentiation capacity if applied solely for immuno-
modulatory purposes. Whether unintended differenti-
ation (as shown in this study and others [30, 31]) has
to be considered a firm risk after systemic application
needs to be assessed separately. Another relevant con-
sequence of ex vivo irradiation may be premature
MSPC senescence resulting in impaired immunomod-
ulatory efficiency in vivo [32].
The pooling of five MSPC and ten PBMC donor sam-
ples to compose the reference pools and the universal
responder pooled PBMCs, respectively, to simultan-
eously measure mitogenesis and MLR was based on
practical considerations. It may be speculated that in-
creasing the number of different MSPCs per reference
(See figure on previous page.)
Fig. 3 Pooled pre-labeled PBMC and pooled reference MSPC make a robust assay format to readout inhibition of T-cell proliferation in an off-the-shelf
potency assay. a, b Pooled carboxyfluorescein pre-labeled random donor peripheral blood mononuclear cell (pPBMC) aliquots seeded in triplicate show
a highly significant mitogen-induced proliferation (phytohemagglutinin (PHA); green bars) compared to minimum proliferation of the unstimulated
pPBMC seeded off-the-shelf in the absence of PHA (dark grey bar) at day 4 (d4). Triplicates of pMSPC composed of cells from five each random donors
(D1–D15) of bone marrow (BM; blue bars), white adipose tissue (WAT; yellow bars) and umbilical cord (UC; red bars) were used as an organotypic MSPC
reference (grey areas) to determine organ-specific highly significant inhibition of mitogen-induced T-cell proliferation compared to individual a cultured
or b freshly thawed individual MSPC from five donors per organ. c, d At day 7 (d7), the potent allo-response of pPBMC (grey bars; for time
course titration see Fig. 1b, c) in the absence of external stimulation was significantly inhibited by some but not all individual MSPCs
compared to the organotypic reference pMSPC (grey areas; same donors and identical color code as in a, b). Differences between c cultured and
d freshly thawed individual or pooled MSPCs were more prominent compared to the inhibition of mitogenesis (in a, b). Significant inhibition of day 4
mitogen-induced (a, b) and day 7 mixed leukocyte reaction (MLR)-induced (c, d) pooled T-cell proliferation is indicated at the right margin of the
graphs; significance of individual donor comparison is indicated by vertical lines. Mean ± SD results at an MSPC:PBMC ratio of 1:3 are shown. *p < 0.05;
**p < 0.01 ***p < 0.001; ****p < 0.0001
Ketterl et al. Stem Cell Research & Therapy  (2015) 6:236 Page 7 of 11
MSPC pool may even improve assay performance. Pre-
selection of highly potent MSPCs as a reference could
result in excluding a profound number of donors due to
apparently inferior potency. From a practical point of
view, using randomly selected MSPC donors for com-
posing a reference MSPC pool may display a realistic
reference. The use of a pool of ten PBMC donors proved
to be practicable based on pilot experiments to achieve a
high number of test aliquots and still maintained the dis-
crimination of mitogenesis and MLR at days 4 and 7,
respectively (Additional file 2: Figure S1B). Processing
ten buffy coats to recover approximately 1 × 1010 PBMCs
which could be efficiently labeled with CFSE in a volume
of 500 mL and produced 200 aliquots of 5 × 107 pooled
pre-labeled test PBMCs was shown to be practicable
(Fig. 2). In a total of 35 experiments the pool of ten PBMCs
showed low variability (mean ± SD, 66.05 ± 11.38 %
PHA-induced day 4 and 73.04 ± 5.44 % MLR-induced
day 7 T-cell proliferation, respectively). Reducing the
number of PBMC donors within a pool will reduce
A
B
Fig. 4 Irradiated MSPC maintain their immunomodulatory potency in vitro and their differentiation capacity in vivo. a Direct comparison of the
inhibition of phytohemagglutinin (PHA)-induced T-cell proliferation (green bar) by non-irradiated bone marrow (BM)-MSPCs (-Rx; blue bars) versus
30 Gy irradiated BM-MSPCs (+Rx; hatched blue bars) immediately after thawing (off-the-shelf use; dark grey area) or after a 3-day rescue culture
(light grey area) showed no significant difference at the three ratios as indicated (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Grey bar shows
mean ± SD of unstimulated pooled T-cell proliferation. One representative experiment out of two is shown. b Representative histologic analysis of
ectopic ossicles derived from native (non-irradiated, upper pictures) and irradiated (Rx; 30 Gy, lower pictures) BM-MSPC (n = 6 per group) 6 weeks
after subcutaneous transplantation into immunocompromized NSG recipient mice. Bone formation via a vascularized cartilage intermediate was
evident in hematoylin and eosin (HE; left panels) as well as Movat’s pentachrome (Movat; middle panels) staining. Vimentin staining (right panels)
indicating persistence of reticular stromal cells (MSPCs) within the ectopic ossicles which showed infiltration by (human (hu.) Vimentin-negative)
murine hematopoiesis as described previously only for native (non-irradiated) BM-MSPCs [27]. Scale bars are 100 μm in main histophotographs
and 1 mm in inserts (showing overview of a section through the entire ossicle; dotted rectangles indicate the regions from where the magnified
main pictures were derived). n.s. Not significant, pPBMC Pooled peripheral mononuclear cell
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the power of the multivalent MLR and thus help to
adjust the strength of the allo-response to be inhib-
ited by MSPCs or other regulatory cells. Our observa-
tion that some MSPC strains display an equal
potency of inhibiting a strong multivalent MLR may
be useful to select potent MSPC donors for the treat-
ment of strong allo-responses, e.g., during severe
graft-versus-host reactions. Current data do not allow
speculating whether a defined number of MHC
mismatches between PBMC donors or a particular
strength of an MLR is required to predict MSPC po-
tency in a therapeutic setting.
MSPCs from different sources have been used for
treating thousands of patients suffering from a plethora
of diseases. Lack of robust potency assays and a still-
limited mechanistic insight into their mode of action
evidently hamper the development of optimized and effi-
cient MSPC therapy strategies. Our prime future goal
will be prospectively testing the validity of this assay in
ongoing clinical trials for the treatment of severe
therapy-refractory graft-versus-host disease and multiple
sclerosis. Determining the predictive value of an im-
munosuppression potency assay will require correlation
of assay results with treatment outcome. Monitoring im-
munosuppressive effects of MSPCs may not be restricted
to immunosuppressive therapies. Given the inherent im-
munomodulatory capacity of MSPCs, such a potency
assay may also help to predict immunosuppressive side
effects of MSPCs when used for co-transplantation to
enhance hematopoietic cell engraftment or during other
types of non-immunologic regenerative therapies. Inhib-
ition of thymic reconstitution and reduced immuno-
globulin levels has recently been found to be associated
with MSPC co-infusion at the time of umbilical cord
blood hematopoietic cell transplantation [33]. It is still
not known whether variability of the MSPC immuno-
suppressive potential correlates with inconsistencies of
their three-lineage differentiation [27]. It is also not clear
whether the level of cytokine and trophic factor secre-
tion by MSPCs correlates with treatment outcome [13].
These points need to be addressed in future analyses
with a particular focus on profiling soluble factors
known to be involved in MSC-derived immune response
modulation including interferons, chemokines and
pro-apoptotic molecules, among others. Based on
our previous observation indicating that epigenetics
can distinguish MSCs from different sources it will
also be interesting to precisely study promotor
methylation status of key immunomodulatory mole-
cules to address questions of epigenetic regulation of
immunomodulation [27].
A thorough understanding of the multiplicity of stro-
mal niche cell functions will also be required for better
predicting clinical effects as well as side effects of these
otherwise easily expandable and widely available cells.
Once established, appropriate potency assays may also
help to gain more detailed insight into the mechanisms
underlying the largely unpredictable variability of MSPC
function, eventually resulting in more efficient advanced
cell therapy products. The potency assay introduced
herein has intentionally been set up to function entirely
animal serum-free using pHPL for replacing fetal bovine
serum. We have previously described an unaffected viral
T-cell immunity when using BM-MSPCs to inhibit T-
cell proliferation in vitro [34]. Provided that this also oc-
curs in vivo the propagation of MSPCs in pHPL rather
than in bovine serum may be preferred for clinical use.
We propose using such a standardized potency
assay as a reference to validate MSPC effectiveness.
Selection of pre-tested highly potent individual or
pooled MSPCs may also offer a valid alternative to
individualized cell therapy strategies. Gamma irradi-
ation, while considered an established safety meas-
ure inhibiting unintended proliferation, was not
sufficient to prohibit chondrogenic and osteogenic
MSPC differentiation thus indicating the need to
identify alternative strategies for blocking unintended
differentiation.
Conclusions
– A robust immunosuppression potency assay has
been established using CFSE pre-labeled pooled
and cryopreserved PBMCs which can be tested
off-the-shelf for mitogenesis-driven lymphocyte
proliferation and MLR. The inhibitory potential
of individual MSPCs was compared to pooled
MSPCs as a reference normalizing donor
variation in this combined assay format.
– Fifteen individual test MSPCs from three organs
displayed significant donor-dependent variability in
their immunosuppressive potency. UC- and WAT-
MSPCs were more potent than BM-MSPCs at inhibit-
ing multidirectional allo-MLR of pooled PBMCs and
also at inhibiting pooled T-cell mitogenesis at a higher
PBMC:MSPC ratio (1:30). A proportion of MSPCs
was sensitive to freeze/thaw damage extending pub-
lished results and indicating validity of this assay.
– Gamma irradiation did not hamper MSPC
immunosuppression capacity. A note of caution was
raised by the observation that irradiated BM-MSPCs
maintained their capacity to differentiate along
chondrogenic and osteogenic lineages in vivo.
Additional files
Additional file 1: Table S1. MSPC Donor age and origin. (DOC 63 kb)
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Additional file 2: Figure S1. Time course of polyclonal T cell proliferation.
(A) Random donor single buffy coat-derived carboxyfluorescein (CFSE)-la-
beled peripheral blood mononuclear cells (PBMC 1–5) were plated in
triplicate and cultured in the absence (PBMC, grey bars) or presence
of phytohemagglutinin (+PHA, green bars) for 4 or 7 days resulting
in significantly donor-variable maximum proliferation. (B) Pooled
PBMC from ten random BC donors (pPBMC) were plated in triplicate
and cultured for 3 to 7 days either without additional stimulation
(grey bars) or in the presence of PHA (green bars) or CD3/CD28-coated
beads (open bars) representing standard stimuli of T-cell proliferation. The
mixed leucocyte reaction in the ten-donor PBMC pool was negligible until
days 3 and 4 but constantly increasing thereafter representing a prototypic
allo-response. (C) To test the hypothesis that pooling of CFSE pre-labeled
cryopreserved responder PBMCs allows for the simultaneous readout of
inhibition of the mitogenic and alloimmunogenic T-cell proliferation by
mesenchymal stem/progenitor cells (MSPC), pooled CFSE pre-labeled
PBMCs were seeded in the absence of MSPCs without (grey bars) or with
PHA (green bars) or in the presence of third party umbilical cord-derived
(UC)-MSPC without (light red bars; inhibition of allo-response) or with PHA
(red bars; inhibition of additional mitogenesis) at an MSPC:PBMC ratio of 1:3.
Time course of proliferation and inhibition of proliferation, respectively, was
measured by flow cytometry depicting the percentage of proliferating CD3+
T cells. Mean ± SD results from representative experiments (n = 5 in A and C;
n = 3 in B). Significant difference are indicated (*p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001). (DOC 148 kb)
Additional file 3: Figure S2. Gating strategy for proliferation analysis.
(A) For accurate analysis of proliferating T cells we combined (i) doublet
discrimination by forward scatter width (FS-W) vs. sides scatter area (SS-A)
plotting with (ii) DNA dye exclusion capability of viable 7AAD-excluding
(negative) cells that display mononuclear FS-A characteristics and (iii) CD3
–APC reactivity to identify T cells. One representative (out of >30 per-
formed assays) is depicted. (B) Representative (iv) control cells (pooled
peripheral blood mononuclear cells, pPBMC, without mitogen) showing
less than 2 % proliferation as indicated by diminished CFSE intensity. (v)
After 4 days of pPBMC stimulation with phytohemagglutinin (+PHA)
typically >60 % of the CD3+ T cells undergo proliferation resulting in
diminution of CFSE through cell division. (vi) Addition of MSPCs in a 1:3
ratio to T cells resulted in inhibition of mitogenesis-induced T-cell
proliferation. Representative CD3/CFSE are shown. (C) CD3/CFSE dot
plots depict representative results illustrating the gating logics for
enumeration of (iv) proliferating pPBMC as a result of multiple
allogeneic mixed leukocyte reactions after 7 days even without PHA
and (vi) representative inhibition of proliferation in the presence of
MSPC in a 1:3 ratio of MSPCs:pPBMCs ratio. (DOC 151 kb)
Additional file 4: Figure S3. Thawing does not significantly hamper
mean MSPC immunosuppressive function. Pooled and carboxyfluorescein
(CFSE) pre-labeled random donor peripheral blood mononuclear cells
(pPBMC) aliquots of 5 × 107 cells were used off-the-shelf immediately
after thawing in RPMI-1640/10 % pHPL and seeded in triplicate in the
absence (grey boxes) or presence of phytohemagglutinin (+PHA; green
boxes). Mesenchymal stem/progenitor cells (MSPCs) from each five
independent bone marrow (BM), white adipose tissue (WAT) and umbilical
cord (UC) donors were added immediately after thawing (dark grey
area) or after a 3-day rescue culture period (light grey area). Box
plots indicate median and quartiles of significant inhibition of
PHA-driven T-cell proliferation by five WAT-MSPC (yellow boxes),
BM-MSPC (blue boxes) and UC-MSPC (red boxes) after 4 days at an
MSPC:PBMC ratio of (A) 1:3, (B) 1:10 and (C) 1:30 (except for BM-MSPC at an
MSPC:PBMC ratio of 1:30). No significant difference (n.s.) was observed
comparing results from freshly thawed MSPC vs. MSPC used after rescue
culture for T-cell inhibition indicating overall efficiency of off-the-shelf MSPC
products except for BM. Assay performance also showed absence of outliers
outside the whiskers (n = 5). (DOC 84 kb)
Additional file 5: Figure S4. MSPC immunosuppressive function is in
part cell contact-dependent. Carboxyfluorescein (CFSE) prelabeled pooled
peripheral blood mononuclear cells (pPBMC) were used after thawing in
RPMI-1640/10 % pHPL in triplicate of 3 × 105 cells/well in the presence of
phytohemagglutinin (+PHA; A, B, C; d4) or in the absence of PHA (D, E, F;
d7). Mesenchymal stem/progenitor cells (MSPC) from three randomly
selected bone marrow (BM, blue bars), white adipose tissue (WAT, yellow
bars) and umbilical cord (UC, red bars) donors were added 24 hours in
advance to the culture vessels. (A, B, C) PHA-induced mitogenesis in the
absence (green bars) or presence of MSPCs in serial dilution as indicated
was measured as percentage of proliferating CD3+ T cells. Inhibition of
T-cell proliferation by decreasing numbers of MSPCs was determined in
96-well flat-bottomed plates in direct cell–cell contact between MSPCs
and pPBMCs (left part of the graphs) as compared to cell contact-
independent co-cultures with MSPCs in the lower compartment and
CFSE-labeled pPBMCs in the transwell insert (grey area, right part of the
graphs) using (A) BM-derived, (B) WAT-derived and (C) UC-derived MSPCs
as regulatory cells in serial dilution as indicated by the MSPC:PBMC ratios
on the x-axis indicating significant inhibition of T-cell proliferation by all
three MSPC sources at most but not all ratios but significantly reduced in
transwell assays for most ratios. (D, E, F) At day 7, the potent allogeneic
MLR of the pPBMCs derived from pooling ten random donor-derived
cells (grey bars) in the absence of external stimulation was significantly
inhibited by all three MSPC sources at some but not all ratios tested.
MSPCs were tested in direct cell–cell contact between MSPCs and pPBMCs
(left part of the graphs) as compared to cell contact-independent co-cultures
(transwell) as described above, accordingly. Significant difference are
indicated (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n = 2).
(DOC 259 kb)
Abbreviations
7-AAD−: 7-aminoactinomycin-D-excluding; BM: Bone marrow;
CFSE: Carboxyfluorescein succinimidyl ester; MHC: Major histocompatibility;
MLR: Mixed leukocyte reaction; MSPC: Mesenchymal stem/progenitor cell;
PBMC: Peripheral blood mononuclear cell; PHA: Phytohemagglutinin;
pHPL: Pooled human platelet lysate; SD: Standard deviation; UC: Umbilical
cord; WAT: White adipose tissue.
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